更正:静脉氯胺酮作为难治性抑郁症辅助治疗的双盲、安慰剂对照、剂量范围试验
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
PubMed 文献 · Mol Psychiatry · 2020-01-01
该文是对一项静脉氯胺酮辅助治疗难治性抑郁症(TRD)的双盲、安慰剂对照、剂量范围试验的更正声明。更正涉及补充图1和补充表1-4的版本重新上传,以反映校样阶段提供的版本。出版方已更新HTML版本并致歉。
要点
- 本文为更正声明,非原始研究或指南。
- 更正内容为补充图1和补充表1-4的版本重新上传。
- 出版方已更新HTML版本并致歉。
核心结论
- 更正声明仅涉及补充材料版本更新,不改变原试验结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Supplementary Figure 1 and Supplementary Tables 1-4 have been re-uploaded so as to reflect the versions supplied during proofs stage. The publisher apologizes for the error in versioning. The HTML version of the paper has been updated.
来源:Mol Psychiatry,查看原文。版权归原作者所有。
引用
- Fava M, Freeman MP, Flynn M, et al. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020. PMID: 30617276. doi:10.1038/s41380-018-0311-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。